The Special Research Edition of the Spring 2021 CMTA Report is available now and full of information for you. Inside, we bring you coverage of every aspect of CMTA-STAR from cross-type initiatives to our demyelinating and axonal research portfolios to clinical trial readiness—and so much more. This special report has everything about CMTA-STAR, all in one issue!
- A Message from CEO Amy Gray
- Building and Paying for a STAR
- Cross-Type Initiatives
- INC Explained
- Marking 38 Years of Growth
- STAR’s Portfolio for Demyelinating CMTs – 1A, 1B, 1X [and Some 4s]
- A Look at 1A STAR Biotech Alliance Partners
- Developing and Characterizing New Mouse Models of CMT1X
- STAR 1A Timeline: CMTA Roadmap to Success
- Pharnext Announces Phase 3 Clinical Trials for 1A
- Clinical Trials – The Road to Drug Approval
- The Challenge of Rare Diseases
- Why We Give: We Believe in the CMTA
- Filling the Pipeline: The CMTA-STAR Funding Process
- STAR’s Portfolio for Axonal CMTs – Type 2 [and Some 4s]
- The CMTA’s Type 2 Gene Discovery Initiatives
- The CMT2A Gene Replacement Therapy Initiative
- CMT2A Researchers on the Way to Being Trial Ready
- Wondering How You Can Get Involved?